Latest Announcements
Ladenburg Acts as Exclusive Placement Agent in the $1.77 Million Warrant Exercise Transaction for Intelligent Bio Solutions Inc.
Transaction Information Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company") announced an agreement between the Company and several investors to exercise certain existing warrants to purchase up to...
Ladenburg Acts as Sole Book-Running Manager in $4.172 Million Underwritten Public Offering for Peraso, Inc.
Transaction Information Peraso Inc. (NASDAQ:PRSO) ("Peraso" or the "Company") announced the closing of its underwritten public offering of common stock, pre-funded warrants, Series A warrants and Series B warrants...
Ladenburg Thalmann Acts as Placement Agent for Immunic, Inc in a Private Placement of up to $240 Million
Transaction Information Immunic, Inc. (Nasdaq: IMUX) announced it has entered into a securities purchase agreement with select accredited investors to purchase shares of common stock (or pre-funded warrants in lieu...
Ladenburg Acts as Exclusive Placement Agent in the $2.5 Million Warrant Exercise Transaction for Palisade Bio, Inc.
Transaction Information Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company") announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the...
Ladenburg Thalmann Acts as Sole Book-Running Manager in $6 Million Underwritten Public Offering for Biodexa Pharmaceuticals PLC
Transaction Information Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the closing of an underwritten public offering of units for gross proceeds of approximately $6.0 million, which includes the full exercise...
Ladenburg Thalmann Acts as Exclusive Financial Advisor to Aileron Therapeutics, Inc. (ALRN) in its Acquisition of Lung Therapeutics, Inc.
On October 31, 2023, Aileron Therapeutics, Inc. (NASDAQ: ALRN) announced the completion of its acquisition of Lung Therapeutics, Inc. Concurrent with the closing of the transaction, a group of accredited investors...
Ladenburg Thalmann acts as Lead Bookrunner for Carlyle Credit Income Fund on its Series A Term Preferred Offering of $30 Million
Ladenburg Thalmann served as Lead Bookrunner for this offering. Since 2017, Ladenburg has led 53 fixed income transactions for BDC/Investment Companies raising over $2.4 Billion. Overall, Ladenburg has...
Ladenburg Acts as Exclusive Placement Agent in $28 Million Private Placement for enVVeno Medical
Transaction Information enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company") announced that it has entered into a securities purchase agreement with certain healthcare focused institutional...
Ladenburg Thalmann Acts as Sole Book-Running Manager in $4.378 Million Underwritten Public Offering for Intelligent Bio Solutions Inc.
Transaction Information Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company") announced the closing of its previously announced underwritten public offering of units (the "Units") for gross proceeds of...
Ladenburg Thalmann Acts as Joint Book-Running Manager for Sonnet BioTherapeutics in its $4.55 Million Follow-On Offering
Transaction Information Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the closing of a follow-on offering of 2,843,750 shares of common stock (or pre-funded warrants to purchase shares of common...
Ladenburg Thalmann Acts as Exclusive Placement Agent in $2 Million Private Placement for Coeptis Therapeutics
Transaction Information Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company") announced that it has entered into a definitive agreement with a single healthcare focused investor for the...
Ladenburg Thalmann Acts as Exclusive Financial Advisor to Ocular Therapeutix, Inc. (Nasdaq: OCUL) in its $82.5 Million Non-Dilutive Financing
Transaction Information Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular Therapeutix", or "the Company), a biopharmaceutical company focused on development and commercialization of innovative therapies for...